CA3229783A1 - Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions - Google Patents

Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Info

Publication number
CA3229783A1
CA3229783A1 CA3229783A CA3229783A CA3229783A1 CA 3229783 A1 CA3229783 A1 CA 3229783A1 CA 3229783 A CA3229783 A CA 3229783A CA 3229783 A CA3229783 A CA 3229783A CA 3229783 A1 CA3229783 A1 CA 3229783A1
Authority
CA
Canada
Prior art keywords
analogue
group
ttds
relaxin
lysine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3229783A
Other languages
English (en)
French (fr)
Inventor
Guido MAGNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
River 2 Renal Corp
Original Assignee
River 2 Renal Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by River 2 Renal Corp filed Critical River 2 Renal Corp
Publication of CA3229783A1 publication Critical patent/CA3229783A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3229783A 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions Pending CA3229783A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163236090P 2021-08-23 2021-08-23
US63/236,090 2021-08-23
US202263332994P 2022-04-20 2022-04-20
US63/332,994 2022-04-20
PCT/US2022/041095 WO2023028008A2 (en) 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Publications (1)

Publication Number Publication Date
CA3229783A1 true CA3229783A1 (en) 2023-03-02

Family

ID=85322130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3229783A Pending CA3229783A1 (en) 2021-08-23 2022-08-22 Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Country Status (7)

Country Link
US (1) US20240400638A1 (enExample)
EP (1) EP4392440A4 (enExample)
JP (1) JP2024532403A (enExample)
AU (1) AU2022334113A1 (enExample)
CA (1) CA3229783A1 (enExample)
MX (1) MX2024002335A (enExample)
WO (1) WO2023028008A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ766762A (en) * 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015001488A (es) * 2012-07-31 2015-04-08 Novartis Ag Tratamiento de la inflamacion utilizando serelaxina.
PE20191716A1 (es) * 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
NZ766762A (en) * 2018-01-31 2026-03-27 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use

Also Published As

Publication number Publication date
US20240400638A1 (en) 2024-12-05
EP4392440A4 (en) 2025-07-30
MX2024002335A (es) 2024-05-23
AU2022334113A1 (en) 2024-03-14
WO2023028008A3 (en) 2023-10-26
EP4392440A2 (en) 2024-07-03
JP2024532403A (ja) 2024-09-05
WO2023028008A2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
US12083164B2 (en) Amylin analogues
TWI669309B (zh) 升糖素及ｇｌｐ－１共激動劑化合物
JP7295871B2 (ja) 修飾された脂質化リラキシンｂ鎖ペプチドおよびその治療的使用
ES2768375T3 (es) Análogos de glucagón
JP6682432B2 (ja) Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2020045362A (ja) グルカゴン−ｇｌｐ−１−ｇｉｐトリプルアゴニスト化合物
CA3229783A1 (en) Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
US10988523B2 (en) Modified lipidated Relaxin B chain peptides and their therapeutic use
US20250243255A1 (en) Crf2 receptor agonists and their use in therapy
CN118510796A (zh) 用于治疗肾脏病症或疾患的松弛素和加压素类似物的组合